Diabetes and Endocrinology

Host: John Buse, MD, PhD
Guest: Seth Berkowitz, MD, MPH

Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of Medicine.

Host: John Buse, MD, PhD
Guest: Ashok Balasubramanyam, MD

Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.

Host: John Buse, MD, PhD
Guest: Jose C. Florez, MD, PhD

Precision medicine may be the future of diabetes treatment. But what’s needed to implement this approach into practice? Here to explore this concept with Dr. John Buse is Dr. Jose Florez, Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital.

Host: John Buse, MD, PhD
Guest: Carolyn Bramante

Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.

Host: John Buse, MD, PhD
Guest: Ania Jastreboff, MD, PhD

In the ongoing battle against obesity, what does the SURMOUNT-1 study tell us about the role of tirzepatide? Dr. Ania Jastreboff, who is an Associate Professor of Medicine and the co-director of Weight Management and Obesity Prevention Program at Yale School of Medicine, chats with Dr. John Buse and this study’s findings.

Host: John Buse, MD, PhD
Guest: Rodica Pop-Busui, MD, PhD

The American Diabetes Association (ADA) published a new consensus report with the American College of Cardiology on heart failure in patients with diabetes. What does this report recommend—and how will these recommendations impact clinical practice? Dr. John Buse speaks with Dr. Rodica Pop-Busui from the University of Michigan about these updated heart failure recommendations.

Host: John Buse, MD, PhD
Guest: Kenneth Cusi, MD, FACP, FACE

The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.

Host: John Buse, MD, PhD
Guest: David Spence, MD

Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Host: Carol Wysham, MD

From newly approved treatments to emerging clinical trial data, Dr. Carol Wysham shares some of the highlights from the American Diabetes Association’s 82nd Scientific Sessions, exploring developments in GLP-1 receptor agonists, barriers to patient use, and more.

Host: John Buse, MD, PhD

The American Diabetes Association and European Association for the Study of Diabetes recently published guidance on the management of hyperglycemia in type 2 diabetes. What does this consensus statement tell us? Tune in to hear from Dr. John Buse about how we should adapt our approach to management.

Host: John Buse, MD, PhD
Guest: Samuel Dagogo-Jack, MD, DSc

Intensive lifestyle interventions have shown to, if not prevent, significantly delay the onset of diabetes. But what do we need to know about these interventions? Joining Dr. John Buse to share clinical data and unravel the impacts of interventions in prediabetic patients is Dr. Samuel Dagogo-Jack from the University of Tennessee Health Sciences Center.

Host: John Buse, MD, PhD
Guest: Domenica M. Rubino, MD

The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.

Host: John Buse, MD, PhD
Guest: Anastasia-Stefania Alexopoulos, MBBS, MHS

Dr. John Buse joins Dr. Anastasia-Stefania Alexopoulos, an endocrinologist, researcher, and Assistant Professor of Medicine in the Department of Medicine at Duke University School of Medicine to share her research on the deintensification of hypoglycemia-inducing medications in diabetic adults.

Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.

Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.

Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.

Emerging research details a rapid rise in type 1 diabetes in children amid the COVID-19 pandemic. But what's causing this to happen? To dive into why, Dr. Carol Wysham is joined by Dr. Jane Kim from the Rady Children's Hospital in San Diego.

Host: Carol Wysham, MD
Guest: Rodica Pop-Busui, MD, PhD

Type 2 diabetes can be reflected in a patient's oral health, but can we say the same for patients with type 1 diabetes? Here to dive into that question and to share her latest findings in oral health in patients with type 1 diabetes is Dr. Rodica Pop-Busui, a Larry D. Soderquist Professor of Diabetes and Vice-chair for Clinical Research in the Department of Internal Medicine and also the Director of Clinical Research, Mentoring and Development of M-Diabetes at the University of Michigan.

Guest: Claresa Levetan, MD

How can we better communicate lifestyle changes and glucose monitoring levels with our diabetic patients? Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares key communication strategies she uses with her patients.

Guest: Claresa Levetan, MD

Diabetes impacts around 40 million Americans and 25% of them don't even know they have it. Luckily, Diabetes Alert Day was created to spread awareness of this widespread disease. To help us understand this campaign, Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares insights on the importance of Diabetes Alert Day.

Host: John E. Anderson, MD
Guest: Scott Pilla, MD, MHS

One of the most serious side effects of diabetes, hypoglycemia can lead to severe consequences, and keeping up with the latest in care can help us prevent this complication. To share the latest updates, Dr. John Anderson is joined by Lead Researcher Dr. Scott Pilla to share insights from his recent studies on hospital utilization and primary care communication for patients with diabetes.

Host: Carol Wysham, MD
Guest: Deepak Vashishth, PhD
Guest: Bowen Wang

Can we predict when a patient with COVID-19 requires hospitalization? To answer this question, Dr. Carol Wysham is joined by Dr. Deepak Vashishth and Mr. Bowen Wang from the Rensselaer Polytechnic Institute to share data from their study on the impact of glycemic levels and common medications on COVID-19 severity in patients with type 2 diabetes.